Activating molecular alterations in the Fibroblast Growth Factor Receptor 3 (FGFR3) gene have been identified through large-scale next generation genomic sequencing efforts across a range of tumour types including urothelial carcinoma, lung squamous cell carcinoma, glioblastoma and myeloma [1,2,3,4]. The gene discussed is FGFR3; the disease is urothelial carcinoma.